[HTML][HTML] When quality beats quantity: decision theory, drug discovery, and the reproducibility crisis
JW Scannell, J Bosley - PloS one, 2016 - journals.plos.org
A striking contrast runs through the last 60 years of biopharmaceutical discovery, research,
and development. Huge scientific and technological gains should have increased the quality …
and development. Huge scientific and technological gains should have increased the quality …
The acute effect of metabolic cofactor supplementation: a potential therapeutic strategy against non‐alcoholic fatty liver disease
…, M Adiels, H Turkez, MR Taskinen, J Bosley… - Molecular systems …, 2020 - embopress.org
The prevalence of non‐alcoholic fatty liver disease ( NAFLD ) continues to increase
dramatically, and there is no approved medication for its treatment. Recently, we predicted the …
dramatically, and there is no approved medication for its treatment. Recently, we predicted the …
[HTML][HTML] Integration of heterogeneous biological data in multiscale mechanistic model calibration: application to lung adenocarcinoma
…, M Coudron, E Tixier, BMW Illigens, J Bosley… - Acta biotheoretica, 2022 - Springer
Mechanistic models are built using knowledge as the primary information source, with well-established
biological and physical laws determining the causal relationships within the …
biological and physical laws determining the causal relationships within the …
Improving the economics of NASH/NAFLD treatment through the use of systems biology
Highlights • We survey the NASH therapies currently in the development. • Systems biology
approaches can be used in integration of heterogeneous omics data. • Systems biology …
approaches can be used in integration of heterogeneous omics data. • Systems biology …
A quantitative systems pharmacology modeling platform for evaluating triglyceride profiles in patients with high triglycerides receiving evinacumab
M Khaksar Toroghi, J Bosley, LM Powell… - CPT …, 2021 - Wiley Online Library
A model to quantitatively characterize the effect of evinacumab, an investigational monoclonal
antibody against angiopoietin‐like protein 3 (ANGPTL3) on lipid trafficking is needed. A …
antibody against angiopoietin‐like protein 3 (ANGPTL3) on lipid trafficking is needed. A …
[HTML][HTML] Empirical methods for the validation of time-to-event mathematical models taking into account uncertainty and variability: application to EGFR+ lung …
…, JL Palgen, A L'Hostis, N Ceres, JP Boissel, J Bosley… - BMC …, 2023 - Springer
Background Over the past several decades, metrics have been defined to assess the quality
of various types of models and to compare their performance depending on their capacity to …
of various types of models and to compare their performance depending on their capacity to …
A quantitative systems pharmacology workflow towards optimal design and biomarker stratification of atopic dermatitis clinical trials
…, L Etheve, E Jacob, C Monteiro, J Bosley… - Journal of Allergy and …, 2024 - Elsevier
Background The development of atopic dermatitis (AD) drugs is confronted by many disease
phenotypes and trial design options, which are hard to explore experimentally. Objective …
phenotypes and trial design options, which are hard to explore experimentally. Objective …
[PDF][PDF] Qualifying mechanistic physiological models for use in pharmaceutical discovery and development
C Friedrich, J Bosley, R Baillie… - ACoP, 2011 - rosaandco.sfo3.digitaloceanspaces …
Christina Friedrich* (1), Rada Savic (2), Jim Bosley (1), Rebecca Baillie (1), Ron Beaver (1) (1)
Rosa & Co LLC, San Carlos, … Christina Friedrich* (1), Rada Savic (2), Jim Bosley (1) …
Rosa & Co LLC, San Carlos, … Christina Friedrich* (1), Rada Savic (2), Jim Bosley (1) …
[PDF][PDF] Multiscale EGFR mutated NSCLC tumor heterogeneity knowledge-based model predicts tumor growth under gefitinib: An avenue to in silico clinical trial
…, E Peyronnet, E Jacob, BMW Illigens, J Bosley… - Cancer …, 2022 - novadiscovery.com
Background Treatment for lung adenocarcinoma (LUAD) patients is complex: mechanistic
modeling based on knowledge could help clinicians testing biological assumptions, and …
modeling based on knowledge could help clinicians testing biological assumptions, and …
[PDF][PDF] Impact of modeling on GPR119 agonist development
METHODS We developed a Physiologically-based model which includes insulin, glucose
and glucagon metabolism as well as GPR119 MOA and efficacy measures. Meals, infusions, …
and glucagon metabolism as well as GPR119 MOA and efficacy measures. Meals, infusions, …
